BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR
70.19
-0.24 (-0.34%)
As of 3:00PM CET. Market open.
Stock chart is not supported by your current browser
Previous Close70.43
Open70.50
Bid70.19 x 28400
Ask70.21 x 2100
Day's Range70.03 - 70.93
52 Week Range52.02 - 73.17
Volume946,732
Avg. Volume2,761,653
Market Cap65.456B
Beta (3Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateOct 30, 2019
Forward Dividend & Yield2.80 (3.97%)
Ex-Dividend Date2019-04-29
1y Target Est120.99
  • Bayer glyphosate plaintiffs double since July
    Reuters Videos

    Bayer glyphosate plaintiffs double since July

    Bayer shares were up on Wednesday But so were the number of US plaintiffs mounting lawsuits against it. 42,700 is more than twice the tally in July ... Potentially raising the level of any future settlement ... With users of Round-up and other glyphosate weedkillers who blame them for their cancer. Bayer has steadfastly argued that glyphosate is safe ... Chief executive Werner Baumann even appeared in a special video in March. (SOUNDBITE) (English) CEO OF BAYER AG, WERNER BAUMANN, SAYING: "We will continue to defend this product vigorously. Glyphosate also has an immense importance for the global food supply." But it is the alleged impact on the food supply and the environment too That has led to multiple protests against the German firm - including a "die-in" in France in May .... And against Monsanto - who Bayer bought last year - and Round-up with it - for 63 billion dollars ... Bayer's results for Q3 show a 7.5 per cent rise in earnings to around 2.6 billion dollars - in line with the market view. A stock price which has lost around 30 per cent since August rose nearly two percent on its earnings news As for its potential glyphosate liabilities: the first three US court rulings awarded tens of millions of dollars to each plaintiff. Analysts currently estimate the size of a future settlement at eight to 12 billion dollars.

  • Unilever Chairman Leaves $162 Billion Role to Run $85 Million Fund
    Bloomberg

    Unilever Chairman Leaves $162 Billion Role to Run $85 Million Fund

    (Bloomberg Opinion) -- And then there were none.Almost exactly a year after Unilever NV announced the departure of chief executive officer Paul Polman, the consumer goods giant’s chairman Marijn Dekkers is stepping down with immediate effect. Nils Andersen, a non-executive director since 2015, will replace him.In one sense it’s a natural time for a change. Dekkers has overseen the CEO succession, with Alan Jope starting last January. Unless something goes horribly wrong, that should be off the agenda for some time. Yet it jars that the chairman is leaving the post immediately after filling it for just three years.Unilever says he wants to concentrate on his responsibilities as founder and chairman of Novalis LifeSciences, an investment and advisory firm for the drugmaking industry. Novalis recently raised $85 million and plans to invest in at least eight companies. The suggestion was that this didn’t leave much time for leading the board of Unilever, whose market value is 147 billion euros ($162 billion).Dekkers, a former CEO of Bayer AG, will stay as a non-executive director. It’s strange nonetheless that Unilever didn’t wait until its annual shareholder meeting in April before standing him down. It’s hard not to link the wholesale change at the top of the Anglo-Dutch company to its botched attempt to simplify into a single Netherlands-based organization.After this unification effort was abandoned last year, the future of Unilever’s dual-headed corporate structure is unresolved. Andersen will need to address this, especially if the company wants to spin off its food business or use its shares to make a big acquisition in the U.S. Having two classes of shares makes this more difficult.That the new chairman is neither British nor Dutch (he’s Danish) is helpful given that the future domicile will probably be on the agenda again. However, hiring an outsider would have been better still for tackling such a profound question; Jope is a Unilever lifer.The new CEO may now find himself confronted by a stronger chairman given that Dekkers was damaged by the unification debacle. Andersen has relevant experience too: He was chief executive of the brewer Carlsberg A/S between 2001 and 2007.Jope has a difficult enough task in accelerating sales growth, which has been stubbornly sluggish despite Unilever’s strong portfolio of brands and enviable emerging market exposure. Making a success of the company’s many acquisitions, from fake meat to premium laundry, is another priority. Integrating these businesses, often created by entrepreneurial founders, into the Unilever culture isn’t easy.Longer term, Jope and Andersen must decide whether to stick with the food business after Unilver sold its spreads arm in 2017, or whether to go all in on the faster growing beauty and personal care brands. If they do decide on radical change, it will need to be better executed than the plan to ditch the British headquartersTo contact the author of this story: Andrea Felsted at afelsted@bloomberg.netTo contact the editor responsible for this story: James Boxell at jboxell@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt
    Simply Wall St.

    Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Moody's

    Bayer AG -- Moody's assigns Baa3 rating to Bayer's new hybrid notes; negative outlook

    Moody's Investors Service ("Moody's") has today assigned a Baa3 long-term rating to the new hybrid securities (the "Hybrids") to be issued by Bayer AG ("Bayer"). The rating of Baa3 is two notches below Bayer's Baa1 senior unsecured rating. This reflects the deeply subordinated ranking of the new hybrid securities in relation to the existing senior unsecured obligations of Bayer or those issued by its subsidiaries and guaranteed by Bayer.

  • Reuters

    German chemicals industry sees no reason for optimism after Q3 revenues drop

    German chemicals association VCI on Wednesday said it saw no positive signals for the chemical industry after reporting a 2.4% drop in third-quarter revenues, citing a weakening auto market, a drop in domestic orders and sluggish global growth. "The situation for the chemical industry is not easy," VCI President Hans Van Bylen said. Production in the chemical and pharmaceutical industries, which are significant contributors to Germany's gross domestic product, fell 0.6% in the third quarter of the year, VCI said, adding that falling prices weighed on third-quarter revenues.

  • Morningstar

    Rounding Up Big Pharma Earnings

    Bayer Shows Strength Across Portfolio as Litigation Concerns Continue Bayer BAYRY reported third-quarter results largely in line with our projections. We continue to view the company as undervalued, with the market attributing too much concern to the ongoing glyphosate litigation.

  • Moody's

    Bayer US Finance II LLC -- Moody's announces completion of a periodic review of ratings of Bayer AG

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bayer AG and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Thomson Reuters StreetEvents

    Edited Transcript of BAYN.DE earnings conference call or presentation 30-Oct-19 9:00am GMT

    Q3 2019 Bayer AG Earnings Press Conference

  • No Bayer Roundup Settlement Anytime Soon, Says Lawyer Who Won in Court
    Bloomberg

    No Bayer Roundup Settlement Anytime Soon, Says Lawyer Who Won in Court

    (Bloomberg) -- Even after three big losses in court trials and a plunge in market value, Bayer AG isn’t close to settling tens of thousands of U.S. lawsuits claiming its Roundup weedkiller causes cancer, according to a lawyer who won one of those cases.Aimee Wagstaff, who helped persuade a jury to award $80 million in damages to a Roundup user earlier this year, said more trials loom in 2020 and Bayer “doesn’t care” that its Monsanto unit lost her case, or the other two. Wagstaff declined to elaborate, though Bayer has insisted publicly Roundup is safe. The German company has appealed the trial losses and said it will continue the fight in court.“I wouldn’t expect any settlement in the near future,” Wagstaff, a Denver-based attorney, told a group of plaintiffs’ lawyers at a Las Vegas convention Oct. 23. “This litigation is far from being over.” She didn’t return phone calls and an email Tuesday seeking additional comment.Bayer has lost more than $30 billion in value since last year’s $63 billion purchase of Roundup creator Monsanto Co. The deal put Bayer Chief Executive Officer Werner Baumann on the hot seat as claims against the weedkiller escalated, raising concern from investors about the cost of resolving the litigation.If the recent court losses are repeated for all the cases, Bayer’s liability could reach hundreds of billions of dollars, though the company would likely pay far less to settle all those claims, said Holly Froum, a Bloomberg Intelligence analyst.Bloomberg News reported in August that Bayer floated a settlement proposal valued at $6 billion to $8 billion to resolve all the lawsuits. Ken Feinberg, a mediator called in by U.S. District Judge Vince Chhabria to facilitate the talks, dismissed the report as “pure fiction.”Bayer declined to comment Tuesday, citing confidentiality of mediation talks, spokesman Tino Andresen said by phone.Read More: Bayer Litigation PrimerAnalysts have estimated the cost of settling all the U.S. lawsuits could be anywhere from $2.5 billion to $20 billion. Some investors say paying less than $10 billion would be worth it.If a deal comes together, it would allay a shareholder revolt following the losses in California courts, which began with an August 2018 verdict in San Francisco. In those cases, the average payouts were almost $50 million per plaintiff, after judges reduced jury verdicts that totaled more than $2.4 billion. After each company loss, thousands of new cases were filed.Bayer said Wednesday that the number of Roundup plaintiffs has risen to 42,700 from 18,400 when it last reported in July. The uptick came as plaintiff attorneys increased their advertising seeking new clients after Bayer entered mediation discussions. The number of lawsuits “says nothing about their merits,” Bayer said while reporting an increase in third-quarter earnings.During her remarks at Mass Torts Made Perfect, a convention that draws thousands of plaintiffs’ lawyers to Las Vegas annually, Wagstaff said Bayer faces about a dozen trials next year over the Roundup cancer claims and lawyers are readying to try them.‘Long Game’“There’s not a settlement right here -- we have to get ready for the long game,” Mike Papantonio, a Florida-based lawyer who hosts the conference, told attendees at the session about Bayer’s Roundup litigation.Two cases in state court in California are set to be the first to go to trial in mid-January, Wagstaff said. Bayer also faces its next federal court case before Chhabria in February. That judge has thousands of Roundup cases consolidated before him for pre-trial information exchanges and test trials, including in other states.The company also faces cases next year in state courts in Missouri, Montana and Hawaii and federal courts in Nebraska, Illinois and North Carolina, Wagstaff said. While the early cases have involved home gardeners or groundskeepers, the Montana case will be the first to focus on claims by a farmer who used the weedkiller on his crops, she said. That case is scheduled for trial in April.The consolidated case is IN RE: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).(Updates with Bayer appeal in second paragraph, new number of plaintiffs in 10th)To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net;Tim Loh in Munich at tloh16@bloomberg.netTo contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Reuters

    UPDATE 3-Bayer says U.S. glyphosate plaintiffs more than double since July

    Germany's Bayer is now facing 42,700 U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer, more than twice the tally in July and potentially raising any future settlement. Bayer, the inventor of aspirin and owner of Yasmin birth control and Claritin allergy relief brands, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion. "The number of lawsuits, first and foremost, doesn't tell us anything about their merits," Chief Executive Werner Baumann said in a media call.

  • Bayer says U.S. glyphosate plaintiffs more than double since July
    Reuters

    Bayer says U.S. glyphosate plaintiffs more than double since July

    Germany's Bayer is now facing 42,700 U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer, more than twice the tally in July and potentially raising any future settlement. Bayer, the inventor of aspirin and owner of Yasmin birth control and Claritin allergy relief brands, is widely expected to eventually buy itself out of the litigation, with analysts currently estimating the size of a future settlement at $8-$12 billion. "The number of lawsuits, first and foremost, doesn't tell us anything about their merits," Chief Executive Werner Baumann said in a media call.

  • Moody's

    Vert Companhia Securitizadora - 1ª, 2ª e 3ª Séries da 39ª Emissão de CRA -- Moody's assigns provisional ratings of (P)Baa3 (sf) / (P)Aaa.br (sf) to the first series of the 39th issuance of Vert Companhia Securitizadora agribusiness certificates, a Brazilian trade receivables securitization

    Moody's América Latina (Moody's) has assigned provisional ratings of (P)Baa3 (sf) (global scale, local currency) and (P)Aaa.br (sf) (national scale) to the first series of the 39th issuance of agribusiness certificates (certificados de recebíveis do agronegócio, or Senior CRA) issued by Vert Companhia Securitizadora (Vert, not rated). The transaction is a securitization program sponsored by Bayer S.A. (Bayer Brazil, not rated), a subsidiary of Bayer AG (long-term rating Baa1, global scale, outlook negative).

  • BASF Beats Estimates as Farming Helps Offset Trade-War Pain
    Bloomberg

    BASF Beats Estimates as Farming Helps Offset Trade-War Pain

    (Bloomberg) -- BASF SE reported third-quarter profit that slightly beat estimates after its 8 billion-euro ($8.9 billion) purchase of agrochemical and seed assets from Bayer AG helped offset an economic slowdown stoked by the U.S.-China trade war.Adjusted earnings before interest and taxes fell 24% to 1.1 billion euros, the Ludwigshafen, Germany-based chemical maker said. Analysts had predicted 1.06 billion euros, according to a Bloomberg survey.Key InsightsAgriculture was the highlight, as that business reported sales growth of 26% on the back of higher volumes in South America, Africa and the Middle East. The acquisition of the Bayer operations helped as well.BASF is battling an array of economic challenges. The company said Thursday that the global industrial economy continued to cool in the third quarter, with the trade war and Brexit uncertainty in particular affecting the U.S. and Europe’s export-focused countries. After earlier cuts, Chief Executive Officer Martin Brudermueller stuck with current full-year targets.BASF’s diverse portfolio of chemicals -- spanning petrochemicals and pesticides to cosmetic ingredients and plastics -- means the company is particularly exposed to the global industrial economy, which is also suffering from a slowdown in China and the decline of the auto industry.The CEO is shaking up the chemical maker by trimming management and jobs, selling peripheral businesses and reallocating about 20,000 workers to customer-facing roles to keep pace with volatile market trends.Market Reaction BASF shares rose 1.9% to 69.06 euros as of 9:36 a.m. in Frankfurt, extending gains for the year to 14%.Get MoreClick here for more information on BASF’s earnings.BASF expects its efficiency drive to deliver a 500 million-euro earnings boost this year. It predicted the program will deliver a 1 billion euro to 1.3 billion euro uplift in 2020.(Updates with share price)To contact the reporter on this story: Andrew Noël in London at anoel@bloomberg.netTo contact the editors responsible for this story: Anthony Palazzo at apalazzo@bloomberg.net, John BowkerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Bayer expects significant surge in number of U.S. glyphosate cases
    Reuters

    Bayer expects significant surge in number of U.S. glyphosate cases

    Bayer expects the number of claims in the United States related to Roundup herbicide to have surged in the third quarter, as the German drugs and pesticides maker tries to reach a settlement after earlier court rulings against it. Bayer, which acquired Roundup and other glyphosate-based weed killers as part of its $63 billion takeover of Monsanto last year, faces potentially heavy litigation costs as plaintiffs claim Roundup causes cancer, something Bayer disputes. Bayer's shares have lost about 30% of their value since last August when a California jury in the first such lawsuit found Monsanto should have warned of the alleged cancer risks.

  • Australian farmer brings legal action vs Bayer over weedkiller: report
    Reuters

    Australian farmer brings legal action vs Bayer over weedkiller: report

    An Australian farmer has launched a legal action against Bayer AG's agricultural chemicals unit Monsanto after being diagnosed with a type of cancer he says was caused by its weedkiller, a lawyer for the man said on Friday. New South Wales farmer Ross Wild was diagnosed with non-Hodgkin's Lymphoma last year after using the weedkiller Roundup on his farming property near the border of NSW and Victoria since 1976, according to his lawyer Tony Carbone, of Melbourne-based Carbone lawyers.

  • Moody's

    Scotts Miracle-Gro Company (The) -- Moody's assigns B1 rating to Scotts' proposed senior unsecured notes; outlook is stable

    Moody's Investors Service ("Moody's") today assigned a B1 rating to The Scotts Miracle-Gro Company's ("Scotts") proposed $400 million senior unsecured notes due 2029. The ratings outlook is stable. The rating outlook is stable.

  • Reuters

    CORRECTED-UPDATE 1-European shares muted as gains in defensives outweigh nerves on trade, Brexit

    European shares were little changed in choppy trade on Monday, after their steepest weekly loss in two months, as bids in defensive shares outweighed nervousness ahead of crucial U.S.-China trade talks and Brexit negotiations. Bayer climbed 1.3% as the company said a pending U.S. lawsuit over claims related to glyphosate-based herbicide Roundup has been delayed until further notice. Bayer's shares helped the healthcare index climb 0.6%, while other defensive stocks popular in times of economic strife - food and beverage and utilities - were also leading gains.